# A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

> **NCT02346370** · PHASE1 · TERMINATED · sponsor: **Halozyme Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PEGylated recombinant human hyaluronidase PH20
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02346370
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-10
- **Primary completion:** 2016-08-09
- **Final completion:** 2016-11-14
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Changing standard of care therapy regimen
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346370, "A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02346370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*